Among these, the BCR–TLR–NF‐κB axis, mammalian target of rapamycin (mTOR)–protein kinase B (Akt) pathway and programmed cell death protein 1 (PD‐1) have already been targeted therapeutically in PCNSL (see Novel therapies subsection). This evidence concerns the gene AKT1 and primary central nervous system lymphoma.